In contrast to the LPS studies, we were able to show in a different transgenic mouse model, the APPSw/NOS2−/− mice that develop amyloid and tau pathologies, that anti-Aβ immunotherapy is able to lower both amyloid and tau pathologies while improving behavioral performance [17]. This evidence concerns the gene MAPT and amyloidosis.